Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.